The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Acute respiratory distress syndrome is a significant complication in critical care patients. COVID-19 (C19)-associated severe respiratory failure is related to it, and d-dimer rise predicts a worse ...

The following is a summary of “Clinical Performance of Spo 2 /Fio 2 and Pao 2 /Fio 2 Ratio in Mechanically Ventilated Acute Respiratory Distress Syndrome Patients: A Retrospective Study,” published in ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

The following is a summary of “Prognostic value of PaO2/FiO2 ratio in predicting clinical outcomes in COVID-19 patients,” published in the June 2024 issue of Critical Care by Canto-Costal et al.

Clinical question: Do the anti-inflammatory and immunomodulatory effects of glucocorticoids decrease mortality among patients with severe community-acquired pneumonia (CAP)? Background: CAP remains a ...

ABSTRACT: Background: Recombinant human soluble thrombomodulin (rhTM) was approved for the treatment of disseminated intravascular coagulation in Japan, and rhTM has anti-inflammatory effects.

The PF ratio (PaO2/FiO2 ratio) is an essential indicator used in medicine to gauge the severity of a patient’s hypoxemic respiratory failure. This value helps healthcare professionals determine ...

The P/F ratio, also known as the PaO2/FiO2 ratio, is a valuable tool for evaluating oxygenation status in critically ill patients. It is commonly used to determine the severity of acute respiratory ...

Infants with persistent pulmonary hypertension of the newborn (PPHN) who have blood type O responded better to inhaled nitric oxide (iNO) vasodilator therapy than those with other blood types, a small ...

Direct Biologics, LLC announced favorable safety, dosing and efficacy results from its Phase 2 clinical trial of ExoFlo™ in hospitalized adult COVID-19 patients with moderate-to-severe acute ...